Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary-Reference-Cited by-同舟云学术

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

Published:2012-06-04 Issue:14 Volume:18 Page:3722-3730
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Thornton Katherine,Kim Geoffrey,Maher V. Ellen,Chattopadhyay Somesh,Tang Shenghui,Moon Young Jin,Song Pengfei,Marathe Anshu,Balakrishnan Suchitra,Zhu Hao,Garnett Christine,Liu Qi,Booth Brian,Gehrke Brenda,Dorsam Robert,Verbois Leigh,Ghosh Debasis,Wilson Wendy,Duan John,Sarker Haripada,Miksinski Sarah Pope,Skarupa Lisa,Ibrahim Amna,Justice Robert,Murgo Anthony,Pazdur Richard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Current Surveillance and Treatment Guidelines for Thyroid Carcinoma;Current Surgery Reports;2024-07-05

3. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro;International Journal of Molecular Sciences;2024-06-19

4. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy;Chemical Biology & Drug Design;2024-05

5. Recent advances in multitarget-directed ligands via in silico drug discovery;Drug Discovery Today;2024-03